Drug General Information (ID: DDIQLGPF91)
  Drug Name Bupropion Drug Info Blinatumomab Drug Info
  Drug Type Small molecule Monoclonal antibody
  Therapeutic Class Antidepressants Antineoplastics/Cd19 Monoclonal Antibodies

 Mechanism of Bupropion-Blinatumomab Interaction (Severity Level: Major)
     Increased risk of lowers seizure threshold Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Bupropion Blinatumomab
      Mechanism Lower seizure threshold Lower seizure threshold
      Key Mechanism Factor 1
Factor Name Lowers seizure threshold
Factor Description The combination of medications that lower the seizure threshold is a factor that makes people with epilepsy more likely to have seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain that can cause changes in your behavior, movements or sensations, and level of consciousness.
      Mechanism Description
  • Increased risk of lowers seizure threshold by the combination of Bupropion and Blinatumomab 

Recommended Action
      Management Extreme caution is advised if bupropion is administered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with a history of seizures or other risk factors for seizures (e.g., head trauma brain tumor severe hepatic cirrhosis metabolic disorders CNS infections excessive use of alcohol or sedatives addiction to opiates, cocaine, or stimulants diabetes treated with oral hypoglycemic agents or insulin). Bupropion as well as concomitant medications should be initiated at the lower end of the dosage range and titrated gradually as needed and as tolerated. The maximum recommended dosage for the specific bupropion formulation should not be exceeded. Bupropion should be discontinued and not restarted in patients who experience a seizure during treatment.

References
1 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
2 Sheehan DV, Welch JB, Fishman SM "A case of bupropion-induced seizure." J Nerv Ment Dis 174 (1986): 496-8. [PMID: 3090199]
3 Canadian Pharmacists Association.
4 Product Information. Wellbutrin (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
5 Gittelman DK, Kirby MG "A seizure following bupropion overdose." J Clin Psychiatry 54 (1993): 162. [PMID: 8486598]
6 Product Information. Wellbutrin SR (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
7 James WA, Lippmann S "Bupropion: overview and prescribing guidelines in depression." South Med J 84 (1991): 222-4. [PMID: 1899294]
8 Masco HL, Kiev A, Holloman LC, Batey SR, Johnston JA, Lineberry CG "Safety and efficacy of bupropion and nortriptyline in outpatients with depression." Curr Ther Res Clin Exp 55 (1994): 851-63.
9 Dufresne RL, Weber SS, Becker RE "Bupropion hydrochloride." Drug Intell Clin Pharm 18 (1984): 957-64. [PMID: 6439541]
10 Product Information. Zyban (bupropion). Glaxo Wellcome, Research Triangle Park, NC.
11 Storrow AB "Bupropion overdose and seizure." Am J Emerg Med 12 (1994): 183-4. [PMID: 8161393]
12 Johnston JA, Lineberry CG, Ascher JA, et al. "A 102-center prospective study of seizure in association with bupropion." J Clin Psychiatry 52 (1991): 450-6. [PMID: 1744061]
13 Rosenstein DL, Nelson JC, Jacobs SC "Seizures associated with antidepressants: a review." J Clin Psychiatry 54 (1993): 289-99. [PMID: 8253696]
14 Pisani F, Spina E, Oteri G "Antidepressant drugs and seizure susceptibility: from in vitro data to clinical practice." Epilepsia 40(Suppl 10) (1999): S48-56. [PMID: 10609604]
15 Product Information. Aplenzin (buPROPion). sanofi-aventis , Bridgewater, NJ.